[Etiological structure and antibiotic sensitivity of the causative agents of puerperal endometritis]. / Etiologicheskaia struktura i chuvstvitel'nost' k antibiotikam vozbuditelei poslerodovogo éndometrita.

The study revealed the dominating role of aerobic-anaerobic microbial associations and in particular the specific role of anaerobic gram positive cocci in development of puerperal endometritis. The data suggested that a definite level of the uterus cavity contamination with microbes, not lower than 10(4)-10(5) CFU/ml or a large number of bacterial associates, not less than 3 was necessary for endometritis development. It was confirmed that pathogenicity of anaerobes increased in the presence of aerobic bacteria. It is concluded that quantitative methods for detecting the main causative agents of endometritis are needed. A set of antibacterial drugs for rational antibacterial therapy of puerperal endometritis is recommended.

[Comparative clinical efficacy of cephotaxim and cefuroxime against the pathogens of inflammation in obstetrics and gynecology]. / Klinicheskaia otsenka tsefotaksima i sravnenie s tsefuroksimom ego aktivnosti v otnoshenii vozbuditelei vospalitel'nykh protsessov v akushersko-ginekologicheskoi klinike.

The use of cephotaxim in the treatment of obstetric and gynecological patients with various infectious complications, as well as in the treatment of newborn infants in the Department of Intensive Therapy showed it to be highly effective in 100 per cent of the cases. The adverse reactions of cephotaxim were observed in 1 out of 43 patients. It should be noted that cephotaxim did not inhibit the host anaerobic indigenous flora. No cases of dysbacteriosis were recorded. Comparative analysis of the data on determination of the MIC of cephotaxim and cephuroxim with respect to various species of opportunistic microorganisms demonstrated that cephuroxim was more active against Staph. aureus, while cephotaxim against Klebsiella. Cephotaxim displayed activity against part of the strains of Ps. aeruginosa and streptococci of group D, which was not common to cephalosporins of the previous generations.

[Effectiveness of using cefuroxime in the obstetrics and gynecology clinic]. / Effektivnost' primeneniia tsefuroksima v akushersko-ginekologicheskoi klinike.

The clinical trials of cefuroxim in the treatment of patients with various postnatal diseases and postoperative complications caused by Staph. aureus, E. coli, Klebsiella or Proteus showed its high efficacy. No adverse reactions of the drug were observed in any of 24 patients. The drug was rapidly absorbed on its intramuscular administration. Its therapeutic concentrations in the blood, milk and urine persisted for 8 hours after a single administration. Cefuroxim may be recommended for the treatment of patients with moderately severe infections. The single dose is 750 mg administered every 8 hours. However, in patients with severe postoperative complications cefuroxim should be used in combination with antibiotics preventing directed selection of the microorganisms resistant to cefuroxim (nonsporulating anaerobic bacteria, Ps. aeruginosa).